Challenges with Voriconazole Prophylaxis for Lung Transplant Recipients (ATC 2026) - Jun 17, 2026 - Abstract #Abstract C300; Pres time: Jun 22, 2026; 02:45 PM - 03:45 PM; Location: Exhibit Hall; "In March 2025, our transplant center changed our preferred regimen from itraconazole x6 months with amphotericin nebulization x1 month to voriconazole x6 months with amphotericin nebulization x1 month...Our CMV prophylaxis strategy is ganciclovir or valganciclovir, transitioned to letermovir after 2 weeks or at time of discharge... Forty-four percent of patients initiated on voriconazole prophylaxis were transitioned to an alternative antifungal due to toxicities (neurologic, hepatic, Qtc prolongation) and a potential drug-interaction. Not all reported toxicities used as a reason to change were clearly due to voriconazole, but generally presented reasonable scenarios in which a change in antifungal was warranted. Continued monitoring of toxicities and challenges with voriconazole prophylaxis at our medical center will be needed to determine if a reassessment of our antifungal prophylaxis protocol is required.Reasons for antifungal change and alternative agents..."
Clinical • Movement Disorders • Transplantation
|
|
N. Pettit; E. Bell; D. Friedman; L. Potter
|